469 related articles for article (PubMed ID: 34503252)
1. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options.
Ferrara B; Pignatelli C; Cossutta M; Citro A; Courty J; Piemonti L
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503252
[TBL] [Abstract][Full Text] [Related]
2. Stroma-targeting strategies in pancreatic cancer: a double-edged sword.
Liu X; Iovanna J; Santofimia-Castaño P
J Physiol Biochem; 2023 Feb; 79(1):213-222. PubMed ID: 36580230
[TBL] [Abstract][Full Text] [Related]
3. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming.
Zhao T; Zhang R; He Q; Zhou H; Song X; Gong T; Zhang Z
Acta Biomater; 2022 Jun; 145():122-134. PubMed ID: 35381402
[TBL] [Abstract][Full Text] [Related]
4. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship.
Weniger M; Honselmann KC; Liss AS
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200666
[TBL] [Abstract][Full Text] [Related]
5. The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC.
Wang D; Li Y; Ge H; Ghadban T; Reeh M; Güngör C
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010993
[TBL] [Abstract][Full Text] [Related]
6. Tumor Stroma as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma.
Lee DU; Han BS; Jung KH; Hong SS
Biomol Ther (Seoul); 2024 May; 32(3):281-290. PubMed ID: 38590092
[TBL] [Abstract][Full Text] [Related]
7. Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits.
Maneshi P; Mason J; Dongre M; Öhlund D
Front Cell Dev Biol; 2021; 9():787485. PubMed ID: 34901028
[TBL] [Abstract][Full Text] [Related]
8. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies.
Perez VM; Kearney JF; Yeh JJ
Front Oncol; 2021; 11():751311. PubMed ID: 34692532
[TBL] [Abstract][Full Text] [Related]
9. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma.
Sato N; Cheng XB; Kohi S; Koga A; Hirata K
Acta Pharm Sin B; 2016 Mar; 6(2):101-5. PubMed ID: 27006892
[TBL] [Abstract][Full Text] [Related]
10. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy.
He X; Chen X; Liu L; Zhang Y; Lu Y; Zhang Y; Chen Q; Ruan C; Guo Q; Li C; Sun T; Jiang C
Adv Sci (Weinh); 2018 May; 5(5):1701070. PubMed ID: 29876225
[TBL] [Abstract][Full Text] [Related]
11. Cancer-Associated Fibroblasts' Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma.
Awaji M; Singh RK
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30832219
[TBL] [Abstract][Full Text] [Related]
12. ECM Composition and Rheology Regulate Growth, Motility, and Response to Photodynamic Therapy in 3D Models of Pancreatic Ductal Adenocarcinoma.
Cramer GM; Jones DP; El-Hamidi H; Celli JP
Mol Cancer Res; 2017 Jan; 15(1):15-25. PubMed ID: 27671335
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicine Strategies for Targeting Tumor Stroma.
Su MC; Nethi SK; Dhanyamraju PK; Prabha S
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627173
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
[TBL] [Abstract][Full Text] [Related]
15. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.
Carvalho TMA; Di Molfetta D; Greco MR; Koltai T; Alfarouk KO; Reshkin SJ; Cardone RA
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885243
[TBL] [Abstract][Full Text] [Related]
16. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.
Wu Y; Zhang C; Jiang K; Werner J; Bazhin AV; D'Haese JG
Front Oncol; 2020; 10():621937. PubMed ID: 33520728
[TBL] [Abstract][Full Text] [Related]
17. Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer.
Feng J; Xu M; Wang J; Zhou S; Liu Y; Liu S; Huang Y; Chen Y; Chen L; Song Q; Gong J; Lu H; Gao X; Chen J
Biomaterials; 2020 May; 241():119907. PubMed ID: 32120315
[TBL] [Abstract][Full Text] [Related]
18. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy.
Yu Q; Qiu Y; Li J; Tang X; Wang X; Cun X; Xu S; Liu Y; Li M; Zhang Z; He Q
J Control Release; 2020 May; 321():564-575. PubMed ID: 32112854
[TBL] [Abstract][Full Text] [Related]
19. Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer.
Brancato V; Comunanza V; Imparato G; Corà D; Urciuolo F; Noghero A; Bussolino F; Netti PA
Acta Biomater; 2017 Feb; 49():152-166. PubMed ID: 27916739
[TBL] [Abstract][Full Text] [Related]
20. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
Yu Y; Schuck K; Friess H; Kong B
Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
